Objective To analyze the application situation of the anti HBV drugs, and provide reference for clinical rational use of drugs and improve the therapeutic effect of liver disease.MethodsBy using the method of hospital management system, the application situation from 2012 to 2016 in our hospital of various types of anti liver disease drugs, including drug name, dosage forms.The specifications, the number of drug, drug cost, drug use quantity, the amount of medication, medication frequency (DDDs), daily drug cost (DDDc) and other indicators were sorted and analyzed.ResultsThe total amount and drug therapy of anti liver disease drug in our hospital showed increasing trend,the annual growth rate of the amount of medication was also showing a rising trend, the 2015 annual growth in the amount of medication for the highest rate, 41.56%.The annual hepatoprotective drugs in various anti proportion are the first in liver disease drug, liver drugs accounted for the largest amount of drugs and the reduced glutathione, the amount of drugs and antiviral drugs in the largest proportion of entecavir.ConclusionThe application of Anti Sense drugs showing a growth trend year by year, the amount of medication of the annual growth rate is higher, suggesting that the incidence rate of liver disease in our province had a rising trend.At the same time, hepatoprotective drugs accounted for relatively large of the existence medicine The phenomenon of substance abuse, clinicians should pay attention to.In the promotion of rational use of anti hepatitis drugs, clinicians and pharmacists should jointly do a good job of drug evaluation, has achieved the effective, reasonable application of drug safety and economic purposes.

Objective To use in our hospital during 2012 to 2016 anti diabetic drugs were investigated in the analysis, and provide the basis for clinical treatment.MethodsThe drug collected in our hospital during 2012 to 2016 anti diabetic drug name, manufacturer, specifications, quantity, amount, amount, using Excel 2007 for data processing, calculation of DDDs (DDDs) and daily cost (DDC).ResultsFrom 2012 to 2016, the antidiabetic drugs in our hospital the total expenses increased from 12 million 311 thousand and 500 yuan to 19 million 467 thousand and 800 yuan, up 58.13% The amount of consumption.The top three anti diabetic drugs for insulin, sulfonylurea, biguanides;DDDs three for insulin, sulfonylureas, alpha glucosidase inhibitors;DDC three drugs was the highest in Epalrestat Tablets, Insulin Glargine Injection, Insulin Aspart 30 Injection.ConclusionThe treatment of diabetes in our hospital during 2012 to 2016 drug use is more reasonable, the insulin dosage, some new oral proportion is increasing.

Objective To ivaluate the effect of low dose spironolactone combined with febuxostat on the treatment of early diabetic nephropathy complicated with hyperuricemia, in order to provide guidance for clinical.Methods206 cases with early diabetic nephropathy complicated with hyperuricemia in Zhongshan hospital affiliated to Fudan University from June 2013 to June 2014, were randomly divided into the control group and the experimental group, 103 cases in each group.The 2 groups were treated with oral hypoglycemic drugs or insulin to control blood sugar, low salt, low fat and low protein diet.At this basis, the control group were treated with low dose of spironolactone, the experimental group were given low dose spironolactone combined with febuxostat, 24 weeks for a course of treatment.The disease related indexes in the two groups were compared before and after treatment.ResultsAfter treatment, the HbAlc, SUA, TC, TG, UAER and the whole blood viscosity were significantly decreased in the experimental group (P<0.05).There was no significant difference among the indexes in the control group before and after treatment.UAER and SUA in the experiment were lower than those in the control group after treatment (P< 0.05), and the differences of HbAlc, TC, TG, HDL-C, LDL-C and hemorheology index in the two groups were not statistically significant.ConclusionBased on the control of blood glucose and diet therapy, it can correct hyperuricemia, regulate blood sugar and blood lipid disorders, correct the hemorheological indexes, which low doses of spironolactone combined with febuxostat in treating early diabetic nephropathy complicated with hyperuricemia, it can protect renal function well, and it is worthy of attention and promotion.

OBJECTIVE:To upgrade the management of the out-patient pharmacy and provide all the patients, doctors and nurses with good service. METHODS: HIS was applied to the real stock management of the out-patient pharmacy in our hospital. RESULTS: Due to the HIS, the amount of drugs was identical with the account; the overstock and stocktaking error rate were greatly decreased, and the account was clear & the supervision was easy. CONCLUSION: The work efficiency and quality of the out-patient pharmacy was greatly improved by the scientific normalized management.

OBJECTIVE:To intensify the scientific inner management of drugs in hospitals,lower the operation cost on drug management and guarantee patients' medication safety.METHODS:The problems occurred in hospital drug management were analyzed,and the method of management by objective and PDCA cyclical method in scientific management were employed to make a target plan in conformity with the three-level drug management model of our hospital and then the management proposal was carried out.RESULTS & CONCLUSIONS:The application of scientific management enhanced hospital drug management level as well as working efficiency,and the quantity of the overdue drugs was lowered by 90.5% in 2008 than in the same period of 2007.

Objective: To establish a quality control model ensuring good stability and compatibility of manually compounded total nutrient admixtures (TNA). Methods: A parenteral nutrition medication order entry system was establish for standardizing nutritional medication usage and supporting physician's TNA prescribing. TNA medication orders were reviewed by pharmacists for validating the stability and compatibility. TNAs were compounded by pharmacists in a standard way following "four factors of sterile compounding" . The goal of quality control was achieved by establishment of the preliminary standard. Results: The quality of manually compounded total nutrient admixtures achieved the goal since pharmacy intravenous admixture service (PIVAS) started on 2003. Conclusions The quality of TNA is well assured while manually compounded by pharmacists in PIVAS.

Heart failure is the terminal stage of all kinds of heart diseases. Despite the use of a variety of traditional drug standard treatment, the prognosis is still not ideal, and there is an urgent need for the update and improvement of new drugs and treatment methods. In recent years, angiotensin receptor-enkephalase inhibitors (Sacubitril/Valsartan), sodium-glucose cotransporter 2 inhibitors (SGLT-2i), soluble guanoside cyclase agonists (Vericiguat) and myocardial myosin activators omecamtiv mecarbil have been developed successively. SGLT2 inhibitors can improve ventricular load, reduce fibrosis and affect myocardial metabolism. sGC agonists play an anti-heart failure role by enhancing l-ARg-No-SGC-CGMP signaling pathway, improving myocardial and vascular function, reversing ventricular hypertrophy and fibrosis, slowing ventricular remodeling, and reducing ventricular afterload through systemic and pulmonary vasodilation. In addition, fineridone, a novel salt corticosteroid receptor antagonist, has also been reported in clinical studies in the field of heart failure. Therefore, it is the direction and hope for the development of heart failure in the future to select appropriate drugs for different types of patients with heart failure and carry out individualized treatment according to the optimized process of heart failure.

Cardiomyopathy is a disease with abnormal myocardial structure and function. For a long time, due to the limited understanding of cardiomyopathies, cardiomyopathies are treated empirically based on symptoms (such as heart failure, arrhythmia, etc.). Over years, with the improvement of diagnosis technology and the discover of disease mechanism, a variety of drugs have been approved, such as tafamidis, patisiran and Inotersen. Many more drugs have completed preliminary safety and efficacy verification and entered Phase III trials. In addition, some cutting-edge technologies are also being developed, such as siRNA drug patisiran, CRISPR/Cas9 gene editing technology drug NTLA-2001, stem cell therapy, etc. This article discusses two cardiac problems that may be caused by cardiomyopathy: myocardial hypertrophy and cardiac remodeling, and introduces the pharmacology and related research of the latest drugs for these diseases.